NOD2 genetic variants and sarcoidosis-associated uveitis

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Davoudi, S., D. Navarro-Gomez, L. Shen, C. Ung, A. Ren, L. Sullivan, M. Kwong, et al. 2016. “NOD2 genetic variants and sarcoidosis-associated uveitis.” American Journal of Ophthalmology Case Reports 3 (1): 39-42. doi:10.1016/j.ajoc.2016.05.005. http://dx.doi.org/10.1016/j.ajoc.2016.05.005. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1016/j.ajoc.2016.05.005                                                                                                                                                                                                                      |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981970                                                                                                                                                                                                  |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Brief report

**NOD2 genetic variants and sarcoidosis-associated uveitis**

Samaneh Davoudi a, Daniel Navarro-Gomez a, Lishuang Shen b, Cindy Ung a, Ai'ai Ren a, Lynn Sullivan a, Mindy Kwong a, Maria Janessian a, Jason Comander a, Xiaowu Gai b, Ann-Marie Lobo c, George N. Papaliodis a, Lucia Sobrin a,*

a Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
b Children’s Hospital, University of Southern California, Los Angeles, CA, USA
c Department of Ophthalmology, University of Illinois-Chicago, Chicago, IL, USA

**Abstract**

**Purpose:** Identifying genetic risk factors for developing sarcoidosis-associated uveitis could provide insights into its pathogenesis which is poorly understood. We determine if variants in NOD2 confer an increased risk of developing uveitis in adults with sarcoidosis.

**Methods:** In this genetic case-control study, 51 total subjects were enrolled: 39 patients diagnosed with sarcoid-related uveitis and 12 patients with systemic sarcoidosis without ocular involvement as controls. Sanger sequencing of the eleven exons of the NOD2 gene was performed on DNA obtained from whole blood. Sanger sequencing data were aligned against the NCBI-RefSeq reference sequence to identify novel mutations in uveitis patients. For common variants, allele frequencies in cases versus controls were compared using the chi-square test.

**Results:** There were no significant differences in NOD2 common variant allele frequencies between sarcoidosis patients with and without uveitis, and none of the pathogenic NOD2 mutations associated with Blau syndrome were found in this cohort. However, four rare, non-synonymous variants were identified in four patients with ocular sarcoidosis and none of the controls. Variants rs149071116, rs35285618, and 16:g.50745164T>C have never been previously reported to be associated with any disease and may be pathogenic. The fourth variant, rs2066845, is associated with Crohn’s disease and psoriatic arthritis.

**Conclusions:** Despite the phenotypic overlap between sarcoidosis and Blau syndrome, none of the established pathogenic NOD2 variants were present in adults with sarcoidosis. However, four novel, rare, non-synonymous variants were identified in four cases with ocular sarcoidosis. Further investigation is needed to explore the potential clinical significance of these polymorphisms.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

**NOD2** mutations have been shown to be responsible for three granulomatous inflammatory diseases: Crohn’s disease, **NOD2**-associated autoinflammatory disease and Blau syndrome [1], Blau syndrome is a systemic Mendelian disease whose diagnostic triad includes uveitis, granulomatous dermatitis, and arthritis [1], and its phenotype overlaps significantly with early-onset sarcoidosis. Because of the similarity between sarcoidosis and Blau syndrome, there is a strong rationale to investigate **NOD2** variation in patients with adult-onset sarcoidosis, particularly those who develop uveitis as this is a characteristic of both disorders. One previous study examined **NOD2** variants in 13 patients with sarcoidosis-associated uveitis [2]. The investigators did not find any of the disease-causing variants associated with Blau syndrome in sarcoidosis patients. The purpose of this study is to investigate **NOD2** variants, including those that have been newly discovered since the previous publication, in a larger sample size of sarcoidosis patients with and without uveitis to determine if there are previously reported mutations or novel mutations in **NOD2** that predispose to ocular involvement.

* This submission has not been published anywhere previously and is not simultaneously being considered for any other publication.

* Corresponding author. Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA.
E-mail address: Lucia_sobrin@meei.harvard.edu (L. Sobrin).

http://dx.doi.org/10.1016/j.ajo.2016.05.005
2451-9936/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Materials and methods

Patients with sarcoidosis were identified from the Ocular Immunology and Uveitis Clinics of the Massachusetts Eye and Ear Infirmary (MEEI). This study was approved by the MEEI Institutional Review Board/Human Studies Committee. Controls were defined as patients with systemic sarcoidosis but no ocular involvement. Cases were defined as having sarcoidosis-related uveitis. Systemic sarcoidosis was defined based on definitive or presumed sarcoidosis by American Thoracic Society (ATS) and the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) statement criteria. With this criteria, diagnosis is established by either: 1) histological confirmation with evidence of disease involvement in either the thorax or two more other organ systems; or 2) characteristic chest radiographs (bilateral hilar lymphadenopathy) plus erythema nodosum or without diagnosis of another explanatory condition after a minimum of 2 years follow up. Presence or absence of uveitis was determined by clinical examination by a fellowship-trained uveitis specialist. Classification of ophthalmic involvement was based on the criteria set forth by the International Workshop on Ocular Sarcoidosis (IWOS). A diagnosis of definitive ocular sarcoidosis was made in the presence of a compatible uveitis with a confirmatory biopsy. Presumed ocular sarcoidosis was defined by a compatible uveitis supported by bilateral hilar lymphadenopathy seen on chest imaging without a biopsy.

Sanger sequencing of the eleven exons of the NOD2 gene were performed on DNA extracted from the participants' blood. Sanger sequencing data were aligned against the NOD2 NCBI-RefSeq reference sequence. DNASTAR SeqMan Pro software was used for quality control filtering, variant calling and analysis. The variants detected in our patients were cross-referenced against NOD2 variants that have been previously associated with Blau syndrome, sarcoidosis or Crohn's disease. They were also annotated to identify novel rare, non-synonymous mutations in NOD2 for potential functional significance using Human BP Codon Resource (HBCR). HBCR uses predicted sequence changes based on Ensembl gene models, and pathogenicity data extracted from a curated database, PolyPhen, Sorting Intolerant From Tolerant (SIFT), the database of Non-Synonymous Functional Prediction (dbNSFP) resource, and Combined Annotation Dependent Depletion (CADD) scores. HBCR also annotates variants with allele frequencies in multiple reference populations.

Baseline demographic and clinical characteristics between cases and controls were compared using the t-test for continuous variables and the chi-square test for categorical variables. For common NOD2 variants, allele frequencies between cases and control were compared using the chi-square test. All statistical analyses were performed in Stata 12.1 (College Station, Texas).

3. Results

51 subjects were enrolled, including 39 patients diagnosed with sarcoid-related uveitis as cases and 12 patients with systemic sarcoidosis without ocular involvement as controls. Table 1 summarizes the clinical characteristics of the patients. The gender, age, race and duration of sarcoidosis were not statistically different between cases and controls (p > 0.05).

In our patients with adult-onset sarcoidosis, we did not identify any of the single amino acid mutations in NOD2 that have been associated with Blau syndrome [1,5]. Table 2 shows all of the polymorphisms in NOD2 identified by sequencing in our patients. In comparing with the previous publication on NOD2 variants in ocular sarcoidosis, there were six variants that led to protein changes that overlapped between the two studies. Four of them were common variants (rs2067085, rs2066842, rs2066843, rs1861759) and we did not find that they were associated with uveitis to a statistically significant degree. The fifth was a rare variant associated with Crohn's disease (rs2066844, MAF = 0.03).

In our cohort, none of the patients with this variant had a history of Crohn's disease. The sixth (rs5743291) was a rare variant associated with early onset sarcoidosis, but the frequency of this allele was not significantly different between those with and without uveitis [minor allele frequencies (MAFs) = 0.067 and 0.068 respectively].

We identified four rare, non-synonymous variants that were present in only one case each. Two, rs149071116 and novel variant NM_022162.1:c.1342T > C (NOD2:p.Ser448Pro), have never been previously associated with any disease. SIFT, a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution will have a phenotypic effect, predicted both variants to be damaging. Polymorphism rs149071116 was identified in a 34-year-old Asian man with anterior uveitis in the right eye and panuveitis and macular edema in the left eye. The patient with variant NM_022162.1:c.1342T > C (NOD2:p.Ser448Pro) was a 36-year-old Caucasian man with panuveitis, choroiditis, peripheral retinopathy and papillitis. He required methotrexate in addition to his prednisone to control his ocular inflammation and also had renal and pulmonary involvement during course of his disease. The third polymorphism, rs35285618, is a low frequency single nucleotide protein (SNP) (MAF = 0.013) located six amino acids downstream of the R702W variant that is associated with Crohn's disease in African Americans [8]. It was predicted to be “possibly damaging” by PolyPhen but “tolerated” by SIFT. It was found in a 40-year old Hispanic man of European descent with bilateral panuveitis, lung, skin, and parotid gland involvement. The fourth polymorphism, rs2066845, is also a low frequency SNP that is associated with Crohn's disease and psoriatic arthritis [7-9]. The patient with this variant was a 64-year-

Table 1
Demographic and clinical characteristics of sarcoidosis patients.

|                    | Sarcoidosis with uveitis (n = 39) | Sarcoidosis without uveitis (n = 12) | P value* |
|--------------------|-----------------------------------|--------------------------------------|---------|
| Age in years, mean (SD) | 56.6 (15.1)                       | 54.2 (6.8)                           | 0.58    |
| Gender             | M                                 | 11                                   | 5       |
|                    | F                                 | 28                                   | 7       |
| Duration of sarcoidosis in years, mean (SD) | 9.1 (7.5)                      | 8.3 (10.3)                           | 0.72    |
| Ethnicity          | CA                                | 28                                   | 10      |
|                    | AA                                | 10                                   | 1       |
|                    | HA                                | 1                                    | 1       |

* Continuous variables compared with the t-test and categorical variables compared with the chi-square test.

SD = standard deviation, M = male, F = female, CA = Caucasian American, AA = African American, HA = Hispanic American.
Table 2
NOD2 variants identified in sarcoidosis patients.

| NOD2 polymorphisms identified in patients with sarcoidosis | Variant allele frequency |
|----------------------------------------------------------|-------------------------|
| HGVS format with chromosome: Position | Common variants (minor allele frequency \(\geq 0.05\)) | Rare variants (minor allele frequency < 0.05) |
| SNP rs ID number | Mutation type | Nucleotide change | Peptide change | Prior associations with disease | Minor allele frequency from 1000 genomes | Sarcoidosis with uveitis N = 39 (allele frequency) | Sarcoidosis without uveitis N = 12 (allele frequency) | P Value |
| 16:g.50731096 C > A | rs2076752 | 5' UTR | 47G > A NM_022162.1:c.-59G > A by VEP | V16 | None | A – 0.14 | 19 (0.24) | 6 (0.18) | 0.59 |
| 16:g.50733374 G > T | rs2076753 | Intron | 74-25G > T | NA | None | T – 0.11 | 16 (0.20) | 5 (0.18) | 0.53 |
| 16:g.50744624 C > T | rs2066842 | Non-syn | 802C > T | P268S | None | T – 0.10 | 13 (0.17) | 4 (0.13) | 0.50 |
| 16:g.50745199 C > T | rs2066843 | Syn | 1377C > T | R459R | None | T – 0.1076 | 15 (0.19) | 5 (0.18) | 0.60 |
| 16:g.50745583 T > G | rs1861759 | Syn | 1761T > G | R587R | None | G – 0.2161 | 28 (0.36) | 7 (0.22) | 0.27 |
| 16:g.50759547 A > T | rs10776861 | Intronic | 2966 + 64A > T | NA | Chronic obstructive pulmonary disease | T – 0.33 | 39 (0.5) | 11 (0.46) | 0.47 |
| **Rare variants (minor allele frequency < 0.05)** | | | | | | | |
| 16:g.50738308 C > T | NA | Syn | 483C > T | F161F | None | T – 0.0026 | 1 (0.01) | 0 (0) | NA |
| 16:g.50741800 C > T | rs149071116 | Non-syn | 575C > T | A192V | None | NA | 1 (0.01) | 0 (0) | NA |
| 16:g.50744638 C > T | rs35090774 | Syn | 815C > T | S272S | None | T – 0.0042 | 1 (0.01) | 0 (0) | NA |
| 16:g.50745164 T > C | NA | Non-syn | 1342T > C | S448P | None | NA | 1 (0.01) | 0 (0) | NA |
| 16:g.50745275 C > T | rs5743274 | Syn | 1453C > T | L485L | None | T – 0.01 | 1 (0.01) | 0 (0) | NA |
| 16:g.50745655 C > T | rs61739632 | Syn | 1833C > T | A611A | Crohn's disease, Ulcerative colitis | T – 0.0026 | 1 (0.01) | 0 (0) | NA |
| 16:g.50745926 C > T | rs2066844 | Non-syn | 2104C > T | R702W | Crohn's disease | T – 0.01 | 2 (0.02) | 1 (0.04) | NA |
| 16:g.5074945 G > A | rs35285618 | Non-syn | 2123G > A | R708H | Crohn's disease | A – 0.005 | 1 (0.01) | 0 (0) | NA |
| 16:g.5074996 C > G | rs5743278 | Non-syn | 2174C > G | 725G | None | G – 0.018 | 1 (0.02) | 1 (0.09) | NA |
| 16:g.50756340 G > C | rs2066845 | Non-syn | 2722C > G | G908R | Crohn's disease | C – 0.004 | 1 (0.01) | 0 (0) | NA |
| 16:g.50757276 G > A | rs5743291 | Non-syn | 2863G > A | V955I | Crohn's disease | A – 0.03 | 6 (0.06) | 4 (0.18) | 0.50 |

**Bold:** Rare, non-synonymous variants that were only in cases.
SNP = Single nucleotide polymorphism, 5' UTR = 5' untranslated region, Syn = Synonymous, Non-syn = Non-synonymous, NA = Not available.

*Rare, non-synonymous variants those were only present in cases.
variants.

rare, non-synonymous variants were identi-

variants were present in adults with sarcoidosis. However, four

and Blau syndrome, none of the Blau syndrome-associated

common.

to Blau syndrome patients in whom pulmonary involvement is not

may be particularly revealing as they may be closer phenotypically

uveitis patients without pulmonary involvement in such a cohort

Including sarcoidosis

variants in a larger cohort could also help to assess whether

variants are not associated with uveitis in

adult-onset sarcoidosis patients. Our sample size, albeit modest,

was larger than the previous study. Our study was also performed

to a time when the annotation of the human genome is more

complete, and we are better able to characterize the frequency and

potential pathogenicity of variants, particularly rare variants.

With this enhanced annotation of the human genome, we did

identify four rare polymorphisms that lead to protein changes and

were found only in patients with uveitis. The identification of these

variants in only those with ocular manifestations is not sufficient to

establish pathogenicity, particularly given their low MAF and the

limited number of controls without uveitis included in this study.

The potential pathogenicity needs to be further explored with

in vitro experiments. Given the significant overlap in phenotype

between Blau syndrome and sarcoidosis and the important role of

NOD2 variation in a variety of inflammatory diseases, exploration of

NOD2 variants in a larger cohort could also help to assess whether

these or other rare variants may contribute to the development of

uveitis in a subset of sarcoidosis patients. Including sarcoidosis

uveitis patients without pulmonary involvement in such a cohort

may be particularly revealing as they may be closer phenotypically

to Blau syndrome patients in whom pulmonary involvement is not

common.

5. Conclusions

Despite the phenotypic overlap between early onset sarcoidosis

and Blau syndrome, none of the Blau syndrome-associated NOD2

variants were present in adults with sarcoidosis. However, four

rare, non-synonymous variants were identified in four cases with

ocular sarcoidosis. Additional investigation with larger cohorts is

needed to explore the potential clinical significance of these

variants.

Financial support

None of the authors have any proprietary interests or conflicts of

interest related to this submission. This study was supported by a

grant from the Massachusetts Lions Eye Research Fund.

Acknowledgement

Funding for this study was provided by a research grant from the

Massachusetts Lions Eye Research Fund and a Core Grant for Vision

Research from the National Eye Institute (5P30EY14104).

References

[1] P. Pillai, L. Sobrin, Blau syndrome-associated uveitis and the NOD2 gene, Semin Ophthalmol 28 (2013) 327–332.

[2] T.M. Martin, et al., Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15), Am J Ophthalmol 136 (2003) 933–935.

[3] Statement on sarcoidosis, Joint statement of the American thoracic society (ATS), the european respiratory society (ERS) and the World association of sarcoidosis and other granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, february 1999, Am J Respir Crit Care Med 160 (1999) 736–755.

[4] C.P. Herbert, N.A. Rao, M. Mochizuki, International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS), Ocul Immunol Inflamm 17 (2009) 160–169.

[5] C. Miceli-Richard, et al., CARD15 mutations in Blau syndrome, Nat Genet. 29 (2001) 19–20.

[6] M. Mitrovic, U. Potocnik, High-resolution melting curve analysis for high-throughput genotyping of NOD2/CARD15 mutations and distribution of these mutations in Slovenian inflammatory bowel diseases patients, Dis Markers 30 (2011) 265–274.

[7] J.P. Hugot, et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease, Nature 411 (2001) 599–603.

[8] Y. Ogura, et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease, Nature 411 (2001) 603–606.

[9] P. Rahman, et al., CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis, Am J Hum Genet. 73 (2003) 677–681.

[10] K. Sugimura, et al., A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews, Am J Hum Genet. 72 (2003) 509–518.

[11] R.H. Duerr, et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, Science 314 (2006) 1461–1463.

[12] M. Economou, et al., Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis, Am J Gastroenterol 99 (2004) 2393–2404.

[13] D. Kinose, et al., A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population, Respirology 17 (2012) 164–171.

[14] S. Lesage, et al., CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease, Am J Hum Genet. 70 (2002) 845–857.

[15] S. Pugazhendhi, et al., NOD2 gene mutations associate weakly with ulcerative colitis but not with Crohn's disease in Indian patients with inflammatory bowel disease, Gene 512 (2013) 309–313.